反应详情

Compound 1D was prepared from 8-(1-allyl-cyclopropanesulfonyl)-4,5-difluoro-6-(2-fluoro-4-iodo-phenyl)-6,8-dihydro-imidazo[4′,5′:3,4]benzo[1,2-d]oxazol-7-one (I-21a: 210 mg, 0.365 mmol) and potassium trimethylsilonolate (50 mg, 0.390 mmol) using procedures analogous to those described above for Compound 1A to afford 150 mg of the product (75% yield). H1NMR (CDCl3, 300 MHz): δ 8.13 (s, 1H), 7.42 (dd, 1H), 7.31-7.25 (m, 1H), 6.80 (s, 1H), 6.43-6.35 (m, 1H), 6.21 (s, 1H), 5.85-5.70 (m, 1H), 5.22-5.14 (m, 2H), 2.83 (d, 2H), 1.28-1.20 (m, 2H), 0.87-0.80 (m, 2H). LCMS: 97.9%, m/z=548.0 (M−1). HPLC: 86.29%.